Search Results
Apr 06, 2026, 04:00 ET K-679: Новый унимицеллярный конъюгат, загруженный антителом и лекарственным средством, демонстрирует опухолеселективную фармакокинетику, обширное внутриопухолевое распределение и превосходную эффективность в доклинических моделях на животных
превосходную эффективность в отношении солидных опухолей, экспрессирующих EGFR, по сравнению с обычными конъюгатами антитело-лекарственное средство (ADC). Данные будут представлены на ежегодном собрании Американской ассоциации по исследованию рака (AACR) 2026 года, которое состоится в Сан-Диего, штат
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: nový konjugát unimicelov s obsahom protilátok a liečiv vykazuje selektívnu farmakokinetiku pre nádory, rozsiahlu intratumorálnu distribúciu a vynikajúcu účinnosť v neklinických zvieracích modeloch.
konvenčných ADC.V neklinických štúdiách preukázal K-679 farmakokinetiku selektívnu pre nádor, rozsiahlu intratumorálnu distribúciu a zhodné priestorové farmakodynamické účinky v xenotransplantátových modeloch v porovnaní s referenčným konjugátom s obsahom protilátky a liečiva (ADC). K-679 tiež
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Nový konjugát unimicely nesoucí protilátku a léčivo vykazuje nádorově selektivní farmakokinetiku, rozsáhlou intratumorální distribuci a vynikající účinnost v neklinických zvířecích modelech
protilátce (DAR) přibližně 45 molekul DM1 na jednu protilátku, což je výrazně více než u konvenčních ADC.V neklinických studiích prokázal K-679 ve srovnání s referenčním konjugátem protilátky a léčiva (ADC) nádorově selektivní farmakokinetiku, rozsáhlou intratumorální distribuci a shodné prostorové farmakodynamické
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET El conjugado K-679 demuestra farmacocinética selectiva para tumores
la de los ADC convencionales.En estudios no clínicos, K-679 ha demostrado farmacocinética selectiva para tumores, una amplia distribución intratumoral y efectos farmacodinámicos espaciales concordantes en modelos de xenoinjerto, en comparación con un conjugado anticuerpo-fármaco (ADC) de referencia.
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: innowacyjny koniugat przeciwciała i miceli będącej nośnikiem leku wykazuje właściwości farmakokinetyczne umożliwiające selektywne oddziaływanie na guzy nowotworowe, rozległe działanie wewnątrz guza i wysoką skuteczność w nieklinicznych modelach zwierzęcych
działanie wewnątrz guza oraz doskonałą skuteczność w przypadku guzów litych z ekspresją EGFR w porównaniu z konwencjonalnymi koniugatami przeciwciało-lek (ADC - antibody drug conjugate). Dane zostaną przedstawione podczas dorocznej konferencji Amerykańskiego Stowarzyszenia Badań nad Rakiem 2026 (AACR, American
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Un nouveau conjugué d'anticorps chargé de Unimicelle présente une pharmacocinétique sélective de la tumeur , une distribution intratumorale étendue et une efficacité supérieure dans les modèles animaux non cliniques.
distribution intratumorale étendue et une efficacité supérieure dans les tumeurs solides exprimant l'EGFR par rapport aux conjugués anticorps-médicaments (ADC) conventionnels. Les données seront présentées lors de la réunion annuelle 2026 de l'American Association for Cancer Research (AACR) qui se tiendra à
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: Ein neuartiges, mit Antikörpern beladenes Unimicelle-Konjugat zeigt Tumor-selektive Pharmakokinetik, weitreichende intratumorale Verteilung und überlegene Wirksamkeit in nicht-klinischen Tiermodellen
2026 | Tagungen | AACRÜber K-679 K-679 ist ein mit Antikörpern beladenes Unimicelle-Konjugat (ADUC), ein neuartiger ADC-Typ, der auf Kowas patentrechtlich geschützter Mizellentechnologie beruht und sich derzeit in der nichtklinischen Entwicklung befindet. Das Konjugat kombiniert
More news about: Kowa Company Ltd.
Apr 06, 2026, 04:00 ET K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
Meeting 2026 | Meetings | AACRAbout K-679 K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa's proprietary micelle technology, currently in nonclinical development. The conjugate combines an anti-EGFR antibody with drug (DM1)-loaded
More news about: Kowa Company Ltd.
Apr 03, 2026, 10:30 ET Next Generation Drug Conjugates (NDCs) Market worth $42.55 billion by 2035 | MarketsandMarkets™
Daiichi Sankyo, Company Limited (Japan), Ionis Pharmaceuticals, Inc. (US), Rakuten Group, Inc. (US), Novo Nordisk (Dicerna Pharmaceuticals) (Denmark), ADC Therapeutics SA (Switzerland), Sanofi (France), Arrowhead Pharmaceuticals (US), and AbbVie, Inc (US).Browse Adjacent Markets:
More news about: MarketsandMarkets
Apr 01, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
Company.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Apr 01, 2026, 07:45 ET TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
initiation of Phase 1b/2 trial of VISTA in NPM1 mut r/r AMLLead ADC Selection1H 2026: Select lead ADC in AML2H 2026: Expect to initiate ADC in vivo proof of concept (POC) studies2H 2026: Anticipate POC data
More news about: TuHURA Biosciences, Inc.
Mar 31, 2026, 19:00 ET NJ Bio, Inc. と味の素バイオファーマサービス、抗体薬物複合体（ADC）開発支援強化に向けた協業を開始
View original content:https://www.prnewswire.com/jp/news-releases/nj-bio-inc-adc-302730697.htmlSOURCE Ajinomoto Bio-Pharma Services
More news about: Ajinomoto Bio-Pharma Services
Mar 31, 2026, 19:00 ET NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
timelines and reduce technical risk. NJ Bio has been recognized as "Best Contract Research Organization (CRO)" for multiple consecutive years at the World ADC Conference. Learn more:
More news about: Ajinomoto Bio-Pharma Services
Mar 31, 2026, 19:00 ET NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
timelines and reduce technical risk. NJ Bio has been recognized as "Best Contract Research Organization (CRO)" for multiple consecutive years at the World ADC Conference. Learn more:
More news about: Ajinomoto Bio-Pharma Services
Mar 31, 2026, 05:40 ET Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
More news about: Akeso, Inc.
Mar 30, 2026, 11:13 ET Guo Guangchang's Letter to Shareholders: "Repair the Roof While the Sun Is Shining" -- Fosun Aims to Go Further with Greater Stability
diseases. Moving forward, Fosun Pharma will continue to strengthen its core technology platforms encompassing antibodies, antibody-drug conjugate ("ADC"), small molecules and cell therapy, while actively expanding its presence in cutting-edge technologies such as radiopharmaceuticals and small nucleic
More news about: Fosun
Mar 30, 2026, 06:39 ET 神州云科舉辦2026年合作伙伴峰會 以夥伴生態協同驅動數碼韌性提升
須兼顧內地信創要求與國際標準，亦需應對日趨收緊的跨區域數據監管環境，「數據主權」與「AI主權」已成企業不可迴避的核心議題，對基礎設施的靈活性、可靠性及安全性提出了前所未有的要求。面對上述挑戰，神州云科憑藉深厚的實踐經驗，推出面向AI時代的新一代應用交付與安全產品體系。該體系以YK ADC 3.0平台為核心，透過基於Token的負載均衡（Token-Based Load Balancing）AI推理服務網關，實現異構算力的精準智能調度，並原生支援模型上下文協議（MCP）及S3協議等主流AI協議，為企業構建穩定、高效且安全的算力基礎設施底座。整套體系涵蓋高可用架構保障業務連續性、DN
More news about: 神州云科
Mar 30, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
this potential first-in-class combination has the potential to enhance durability of IDEAYA's TOP1-payload based ADC pipeline, including IDE849 and IDE034 (Phase 1 B7H3/PTK7 Bispecific TOP1 ADC).DLL3 has been reported to be upregulated in multiple solid tumor types, including in SCLC, NETs, NSCLC,
More news about: IDEAYA Biosciences, Inc.
Mar 26, 2026, 23:54 ET Akeso Reports Full-Year 2025 Financial Results
point/dual-pathway blockade. On the ADC front, the Company's next-generation candidates, notably bispecific ADC AK146D1 and novel ADC AK138D1, are purpose-engineered to overcome the narrow therapeutic window that chronically plagues current ADCs, advancing the field into ADC 2.0.Phase II trials combining
More news about: Akeso, Inc.
Mar 26, 2026, 15:11 ET Keymed Biosciences gibt die Ergebnisse für das Geschäftsjahr 2025 und aktuelle Geschäftszahlen bekannt
Einnahmen aus dem Verkauf von Kangyueda® auf etwa 315 Mio. RMB.CMG901 (AZD0901, ein First-in-Class-Antikörper-Wirkstoff-Konjugat (ADC) gegen Claudin 18.2): Nach der Auslizenzierung an AstraZeneca für die globale Entwicklung werden mehrere globale klinische Studien der Phase III zügig
More news about: Keymed
Mar 26, 2026, 15:08 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
informe, los ingresos por ventas de Kangyueda® ascendieron a aproximadamente 315 millones de RMB.CMG901 (AZD0901, (un ADC de Claudina 18.2, el primero de su clase): Tras su concesión de licencia a AstraZeneca para su desarrollo global, se están llevando a cabo rápidamente
More news about: Keymed
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
Period, revenue for sales of Kangyueda® amounted to approximately RMB315 million.CMG901 (AZD0901, a first-in-class Claudin 18.2 ADC): Following its out-licensing to AstraZeneca for global development, multiple global Phase III clinical trials are being rapidly advanced. In February
More news about: Keymed
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
sustained momentum for subsequent in-house R&D and pipeline advancement.CMG901 (AZD0901, Claudin 18.2 ADC), a first-in-class Claudin 18.2 ADC globally, has received Fast Track and Orphan Drug Designations from the FDA, as well as Breakthrough Therapy Designation from the CDE.
More news about: Keymed
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
proprietary in-house ADC platform features optimized linkers for tumor-selective payload release and supports multiple Pipeline 2.0 ADC assets, including CS5007 (EGFR/HER3 bispecific ADC), CS5008 (DLL3/SSTR2 bispecific ADC), CS5006 (ITGB4 ADC), CS5009 (B7H3/PD-L1 bispecific ADC), etc.In May 2025,
More news about: CStone Pharmaceuticals
Mar 26, 2026, 06:00 ET Innovent Announces 2025 Annual Results and Business Updates
Phase 2 trial in IO-naïve mucosal/acral melanoma is underway in China. PoC studies in 1L NSCLC and 1L CRC are ongoing.IBI343 (CLDN18.2 ADC): Cornerstone for gastrointestinal cancers, potential TAM over US$8 billionInterim analysis from the China-Japan Phase 3 clinical
More news about: Innovent Biologics